TipRanks
Advertisement
Advertisement

PHVS Stock Latest News

What PolyPid’s Bold Moves in Europe Could Mean for D-PLEX₁₀₀’s Global Potential (NASDAQ: PYPD)
TipRanks NewswireWhat PolyPid’s Bold Moves in Europe Could Mean for D-PLEX₁₀₀’s Global Potential (NASDAQ: PYPD)
14d ago
PHVS
PYPD
Pharvaris’ deucrictibant shows efficacy in published Phase 3 HAE trial
PremiumThe Fly
Pharvaris’ deucrictibant shows efficacy in published Phase 3 HAE trial
14d ago
PHVS
Analyst Reiterates Buy on Strong Deucrictibant Data and Undervalued Angioedema Opportunity; Maintains $60 Price Target
PremiumRatings
Analyst Reiterates Buy on Strong Deucrictibant Data and Undervalued Angioedema Opportunity; Maintains $60 Price Target
17d ago
PHVS
Pharvaris price target raised to $44 from $40 at Guggenheim
PremiumThe Fly
Pharvaris price target raised to $44 from $40 at Guggenheim
1M ago
PHVS
BioCryst downgraded to Sector Perform from Outperform at RBC Capital
PremiumThe Fly
BioCryst downgraded to Sector Perform from Outperform at RBC Capital
1M ago
BCRX
PHVS
Pharvaris price target raised to $50 from $42 at Wedbush
PremiumThe FlyPharvaris price target raised to $50 from $42 at Wedbush
1M ago
PHVS
Pharvaris price target raised to $65 from $50 at Leerink
Premium
The Fly
Pharvaris price target raised to $65 from $50 at Leerink
1M ago
PHVS
Pharvaris price target raised to $62 from $52 at RBC Capital
Premium
The Fly
Pharvaris price target raised to $62 from $52 at RBC Capital
1M ago
PHVS
Pharvaris price target raised to $62 from $46 at Morgan Stanley
PremiumThe Fly
Pharvaris price target raised to $62 from $46 at Morgan Stanley
1M ago
PHVS
Pharvaris price target raised to $65 from $55 at Wells Fargo
PremiumThe Fly
Pharvaris price target raised to $65 from $55 at Wells Fargo
1M ago
PHVS
Pharvaris price target raised to $65 from $52 at Jones
PremiumThe Fly
Pharvaris price target raised to $65 from $52 at Jones
1M ago
PHVS
Pharvaris price target raised to $79 from $75 at Citizens
PremiumThe Fly
Pharvaris price target raised to $79 from $75 at Citizens
1M ago
PHVS
Pharvaris: Strong Phase 3 Data for Deucrictibant XR, but Commercial Hurdles Justify Hold Despite Price Target Increase to $44
PremiumRatingsPharvaris: Strong Phase 3 Data for Deucrictibant XR, but Commercial Hurdles Justify Hold Despite Price Target Increase to $44
1M ago
PHVS
Pharvaris price target raised to $75 from $50 at Oppenheimer
Premium
The Fly
Pharvaris price target raised to $75 from $50 at Oppenheimer
1M ago
PHVS
Midday Fly By: Amazon dominates headlines with Qualcomm pact, cargo flight crash
Premium
The Fly
Midday Fly By: Amazon dominates headlines with Qualcomm pact, cargo flight crash
1M ago
GE
ABM
Pharvaris Affirmed as Emerging Oral HAE Leader on Strong Phase 3 Data; Buy Rating Reiterated with Unchanged $60 Price Target
PremiumRatings
Pharvaris Affirmed as Emerging Oral HAE Leader on Strong Phase 3 Data; Buy Rating Reiterated with Unchanged $60 Price Target
1M ago
PHVS
Pharvaris rises 16.7%
PremiumThe Fly
Pharvaris rises 16.7%
1M ago
PHVS
Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones
PremiumCompany Announcements
Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones
1M ago
6K
PHVS
Morning Movers: Novartis slumps after HARBOR study misses primary endpoint
PremiumThe Fly
Morning Movers: Novartis slumps after HARBOR study misses primary endpoint
1M ago
BSX
HLF
Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR
PremiumCompany AnnouncementsPharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR
1M ago
6K
PHVS
Pharvaris announces positive topline data from deucrictibant in HAE attacks
Premium
The Fly
Pharvaris announces positive topline data from deucrictibant in HAE attacks
1M ago
PHVS
Buy Rating Reaffirmed as Deucrictibant Advances Toward Key Phase 3 Readout; $52 Price Target Maintained
Premium
Ratings
Buy Rating Reaffirmed as Deucrictibant Advances Toward Key Phase 3 Readout; $52 Price Target Maintained
2M ago
PHVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >